secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001493152-24-044006
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in
--------------------------------------------------------------------------------

- Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.
- LP-300 Harmonic trial: 86% clinical benefit rate, 43% objective response in 7-patient lead-in; expanded to Japan and Taiwan.
- LP-184 Phase 1a: 9 cohorts dosed, no DLTs; FDA Fast Track for GBM; Phase 1b/2a expected early 2025.
- LP-284 Phase 1a: fourth cohort dosing, no DLTs; additional hematology sites planned; potential Phase 1b/2 by mid-2025.
- R&D expenses $3.7M (up from $2.2M); G&A $1.5M ($1.3M); 10.8M shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315224044006/0001493152-24-044006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315224044006/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer